Chris Hibberd

Biography
Chris Hibberd has more than 20 years of diagnostics and biopharmaceutical experience in company formation, clinical and business development and commercialization. Prior to taking the helm of Nucleix, he was CEO and co-founder of Astute Medical. He managed a team and secured funding to support a product pipeline that included the launch of NephroCheck®, the first FDA cleared diagnostic for acute kidney injury risk, until its acquisition by bioMérieux. Prior to Astute Medical, he was SVP of corporate development at Biosite, where he managed business development activities that included cofounding Biosite Discovery, a world-class antibody capabilities collaboration, and Biosite’s $1.7 billion acquisition by Inverness Medical. Prior to that, he was a manager at The Boston Consulting Group and a development engineer at Albright & Wilson Americas. He obtained an MBA from the University of Western Ontario and a B.A.Sc. in chemical engineering from the University of Toronto.

Liquid Biopsy Showcase:
Nucleix
Nucleix is revolutionizing cancer treatment by leveraging its highly sensitive PCR and NGS-based EpiCheck® platform to find crucial markers and develop cost-effective screening tests for bladder and lung cancers – helping detect cancer earlier and potentially provide long-term benefit for patients.

EpiCheck®, Cancer Detection At The Earliest Moment
Sensitivity is crucial for early cancer detection. In this talk, Nucleix will outline how it leverages its highly sensitive PCR and NGS-based platforms to find the most important markers and then develop cost-effective PCR-based cancer screening tests for bladder and lung cancers. Highly sensitive tests in cancers like Lung Cancer have the potential to increase screening compliance and drive more patients to treatment when it has the greatest chance of providing long-term benefit.